WesBanco Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

WesBanco Bank’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,000	Closed	-$1.98M	–	683
2026 Q1	$1.98M	Hold	35,000	–	–	0.05%	241
2025 Q4	$2.08M	Hold	35,000	–	–	0.06%	225
2025 Q3	$1.9M	Hold	35,000	–	–	0.05%	253
2025 Q2	$1.92M	Buy	35,000 +19,000	+119%	+$1.12M	0.06%	238
2025 Q1	$1.13M	Buy	+16,000	New	+$1.08M	0.04%	291

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

WesBanco Bank's BMRN Position: Q2 2026 in Review

WesBanco Bank sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 35,000 shares — an estimated $1.98M sold.

WesBanco Bank first reported a position in BMRN in Q1 2025 and held it in 5 quarters. The position peaked at $2.08M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

WesBanco Bank reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
WesBanco Bank sold 35,000 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.98M.
WesBanco Bank first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 5 quarters.
WesBanco Bank's BioMarin Pharmaceuticals position peaked at $2.08M in Q4 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on WesBanco Bank's 13F filing for Q2 2026, filed 28 Jul 2026.